![Fig. 3. Clinical course and follow-up of clonotypic CDRIII DNA in the plasma of a patient with mantle cell lymphoma (patient no. 1,293, A) and a patient with centroblastic lymphoma (patient no. 581, B). The clinical course is indicated as active disease (solid bar), partial remission (grey bar), and complete remission (open bar). Treatment periods are indicated by boxes (CHOP, high-dose BCNU, etoposide, cytarabine, and melphalan [BEAM], followed by autologous peripheral blood stem cell transplantation, and methotrexate [MTX] and prednisone). Plasma was analyzed at diagnosis (DX ) and on five occasions during follow-up, given in weeks. Clinical response to high-dose chemotherapy, but not to standard CHOP treatment is paralleled by loss of detectable CDRIII DNA in the plasma. MW indicates molecular weight markers.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/90/12/10.1182_blood.v90.12.4953/3/bl_0025f3.jpeg?Expires=1724246917&Signature=NO57j~bi97rUD5QYpvaH-BFOQcOvk~Q1tFj7c-3~G6ZTkfL34d8tO896tMgxAfC~sNrrRRo3yOkjokhmp~uTrSB15kFHahk1IHH2UX5HkKz4m5qT2PMzPL62pjfDIBY7~dKZ0pFzUmQgK35T1xqCSD5yEtpZ-e2~rWN~J4FPsQCcp2JXyas7GzbINdlBakxoco6Dy3sJGCWTkadX0LrqLVbeZVUGMQs1do0QW1YnfvJEAjF4fAYxdg9klkwk3M5xSAGBTfCdDkr3Mg92aETVv3tCPch4OHqknSfbYgRtshnz~fMsnMSoGxgAuuiT~YycFwEpE2Ux9iZg7fONkNb6Jw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Clinical course and follow-up of clonotypic CDRIII DNA in the plasma of a patient with mantle cell lymphoma (patient no. 1,293, A) and a patient with centroblastic lymphoma (patient no. 581, B). The clinical course is indicated as active disease (solid bar), partial remission (grey bar), and complete remission (open bar). Treatment periods are indicated by boxes (CHOP, high-dose BCNU, etoposide, cytarabine, and melphalan [BEAM], followed by autologous peripheral blood stem cell transplantation, and methotrexate [MTX] and prednisone). Plasma was analyzed at diagnosis (DX ) and on five occasions during follow-up, given in weeks. Clinical response to high-dose chemotherapy, but not to standard CHOP treatment is paralleled by loss of detectable CDRIII DNA in the plasma. MW indicates molecular weight markers.
